U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Naltrexone for extended-release injectable suspension (marketed as Vivitrol) Information
  1. Postmarket Drug Safety Information for Patients and Providers

Naltrexone for extended-release injectable suspension (marketed as Vivitrol) Information


Vivitrol (naltrexone) is a prescription injectable medicine used to treat alcohol dependence and to prevent relapse to opioid dependence, after opioid detoxification.

Adverse reactions or quality problems experienced with the use of this Product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.

Labeling and Regulatory History from Drugs@FDA

Back to Top